SCHEMBL7183753

SCHEMBL7183753

O=POCCOC(C(=O)c1c(Cl)cccc1Cl)c1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
POLB P06746 2/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
FEN1 P39748 1/20 0.34
KCNQ2 O43526 1/20 0.34
PPARA Q07869 1/20 0.34
CASR P41180 1/20 0.33
THRB P10828 1/20 0.33
PBRM1 Q86U86 1/20 0.33
HTR1D P28221 2/20 0.33
CYP3A4 P08684 1/20 0.33
HDAC7 Q8WUI4 1/20 0.32
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
FABP3 P05413 1/20 0.32
FABP4 P15090 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7177121 0.92 TRPM4 (0.38) ALDH1A1NPC1RAB9APOLBMAPT
SCHEMBL7176044 0.90 FABP4 (0.40) ALDH1A1NPC1RAB9APOLBMAPT
SCHEMBL7181535 0.84 L3MBTL1 (0.40) ALDH1A1NPC1RAB9APOLBSMN1; SMN2
SCHEMBL7181341 0.82 CA12 (0.42) ALDH1A1POLBMAPTSMN1; SMN2KMT2A
SCHEMBL7187015 0.81 ALDH1A1 (0.35) ALDH1A1POLBSMN1; SMN2CYP3A4KMT2A
SCHEMBL7183312 0.80 LMNA (0.38) ALDH1A1MAPTSMN1; SMN2PPARACYP3A4
SCHEMBL7735689 0.77 LMNA (0.35) ALDH1A1NPC1RAB9APOLBSMN1; SMN2
SCHEMBL7181149 0.77 HPGD (0.39) ALDH1A1NPC1RAB9APOLBMAPT
SCHEMBL11602139 0.70 ALDH1A1 (0.61) ALDH1A1NPC1RAB9APOLBMAPT
SCHEMBL23088992 0.69 FEN1 (0.46) ALDH1A1NPC1RAB9AFEN1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ALDH1A1 3416/4885NPC1 772/4885RAB9A 1818/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ALDH1A1 3984/4885NPC1 872/4885RAB9A 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.